Hemorrhagic Fever - 110 Studies Found
Completed |
: Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS : Infection : 2015-02-03 : Drug: Hantavax injection Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 |
Active, not recruiting |
: Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans : Crimean-Congo Hemorrhagic Fever : 2017-01-11 :
|
Enrolling by invitation |
: Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities :
: 2009-10-08 : Drug: Ribavirin (Virazole) Injection The drug is to be adm |
Enrolling by invitation |
: Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever : Viral Hemorrhagic Fever : 2015-06-24 : Drug: Ribavirin |
Completed |
: Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) : Hemorrhagic Fever, Ebola : 2014-10-31 : Biological: rVSVΔ-ZEBOV-GP single dose of rVSVΔ-ZEBOV-GP (3x10^6 pfu, 2x10^7 pfu or 3x10^5) |
Completed |
: STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) : Hemorrhagic Fever, Ebola : 2015-02-19 : Biological: rVSVΔG-ZEBOV The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV iso |
Active, not recruiting |
: Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda : Hemorrhagic Fever, Ebola : 2015-01-29 :
|
Recruiting |
: Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo : Hemorrhagic Fever, Ebola : 2016-01-08 :
|
Recruiting |
: Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo : Hemorrhagic Fever, Ebola : 2015-11-04 :
|
Completed |
: Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea : Hemorrhagic Fever, Ebola : 2015-01-12 : Other: Convalescent Plasma Patients will be treated with plasma from recovered EVD patients. |